This work is licensed under the Creative Commons Attribution 4.0 International License.
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-63. DOI: 10.3322/caac.21834Search in Google Scholar
Crawford ED, Heidenreich A, Lawrentschuk N, Tombal B, Pompeo ACL, Mendoza-Valdes A, et al. Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. Prostate Cancer Prostatic Dis. 2019;22(1):24-38. DOI: 10.1038/s41391-018-0079-0Search in Google Scholar
Shiner A, Sperandio RC, Naimi M, Emmenegger U. Prostate Cancer Liver Metastasis: An Ominous Metastatic Site in Need of Distinct Management Strategies. J Clin Med. 2024;13(3). DOI: 10.3390/jcm13030734Search in Google Scholar
Descotes JL. Diagnosis of prostate cancer. Asian J Urol. 2019;6(2):129-36. DOI: 10.1016/j.ajur.2018.11.007Search in Google Scholar
Merriel SWD, Pocock L, Gilbert E, Creavin S, Walter FM, Spencer A, et al. Systematic review and meta-analysis of the diagnostic accuracy of prostate-specific antigen (PSA) for the detection of prostate cancer in symptomatic patients. BMC Med. 2022;20(1):1-11. DOI: 10.1186/s12916-021-02230-ySearch in Google Scholar
Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per Milliliter. N Engl J Med. 2004 May 27;350(22):2239-46. DOI: 10.1056/NEJMoa031918Search in Google Scholar
Sandhu GS, Andriole GL. Overdiagnosis of prostate cancer. J Natl Cancer Inst - Monogr. 2012;2011(45):146-51. DOI: 10.1093/jncimonographs/lgs031Search in Google Scholar
Dunne JC, Lamb DS, Delahunt B, Murray J, Bethwaite P, Ferguson P, et al. Proteins from formalin-fixed paraffin-embedded prostate cancer sections that predict the risk of metastatic disease. Clin Proteomics. 2015;12(1). DOI: 10.1186/s12014-015-9096-3Search in Google Scholar
Gao Y, Wang YT, Chen Y, Wang H, Young D, Shi T, et al. Proteomic tissue-based classifier for early prediction of prostate cancer progression. Cancers (Basel). 2020;12(5):1-21. DOI: 10.3390/cancers12051268Search in Google Scholar
Bărar AA, Pralea IE, Maslyennikov Y, Munteanu R, Berindan-Neagoe I, Pîrlog R, et al. Minimal Change Disease: Pathogenetic Insights from Glomerular Proteomics. Int J Mol Sci. 2024 May 21;25(11):5613. DOI: 10.3390/ijms25115613Search in Google Scholar
Bărar AA, Pralea IE, Berindan-Neagoe I, Pirlog R, Nutu A, Maslyennikov Y, et al. Proteomic patterns in glomerular research, a laser capture microdissection and liquid chromatography-tandem mass spectrometry approach. Rev Rom Med Lab. 2023 Oct 1;31(4):263-74. DOI: 10.2478/rrlm-2023-0029Search in Google Scholar
Pang Z, Zhou G, Ewald J, Chang L, Hacariz O, Basu N, et al. Using MetaboAnalyst 5.0 for LC-HRMS spectra processing, multi-omics integration and covariate adjustment of global metabolomics data. Nat Protoc. 2022;17(8):1735-61. DOI: 10.1038/s41596-022-00710-wSearch in Google Scholar
Xie Z, Bailey A, Kuleshov M V., Clarke DJB, Evangelista JE, Jenkins SL, et al. Gene Set Knowledge Discovery with Enrichr. Curr Protoc. 2021;1(3):1-84. DOI: 10.1002/cpz1.90Search in Google Scholar
Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Tissue-based map of the human proteome. Science (80- ). 2015;347(6220). DOI: 10.1126/science.1260419Search in Google Scholar
Hernández J, Thompson IM. Prostate-specific antigen: A review of the validation of the most commonly used cancer biomarker. Cancer. 2004;101(5):894-904. DOI: 10.1002/cncr.20480Search in Google Scholar
Henshall SM, Horvath LG, Quinn DI, Eggleton SA, Grygiel JJ, Stricker PD, et al. Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy. J Natl Cancer Inst. 2006;98(19):1420-4. DOI: 10.1093/jnci/djj378Search in Google Scholar
Zhang AY, Grogan JS, Mahon KL, Rasiah K, Sved P, Eisinger DR, et al. A prospective multicentre phase III validation study of AZGP1 as a biomarker in localized prostate cancer. Ann Oncol. 2017;28(8):1903-9. DOI: 10.1093/annonc/mdx247Search in Google Scholar
Eguchi T, Sogawa C, Ono K, Matsumoto M, Tran MT. Cell Stress Induced Stressome Release Including. Cells. 2020;9(755). DOI: 10.3390/cells9030755Search in Google Scholar
Shorning BY, Dass MS, Smalley MJ, Pearson HB. The PI3K-AKT-mTOR pathway and prostate cancer: At the crossroads of AR, MAPK, and WNT signaling. Int J Mol Sci. 2020;21(12):1-47. DOI: 10.3390/ijms21124507Search in Google Scholar
Cutruzzolà F, Giardina G, Marani M, Macone A, Paiardini A, Rinaldo S, et al. Glucose metabolism in the progression of prostate cancer. Front Physiol. 2017;8(FEB). DOI: 10.3389/fphys.2017.00097Search in Google Scholar
Sheng T, Li C, Zhang X, Chi S, He N, Chen K, et al. Activation of the hedgehog pathway in advanced prostate cancer. Mol Cancer. 2004;3:1-13. DOI: 10.1186/1476-4598-3-29Search in Google Scholar
Pircher A, Schäfer G, Eigentler A, Pichler R, Puhr M, Steiner E, et al. Robo 4-the double-edged sword in prostate cancer: Impact on cancer cell aggressiveness and tumor vasculature. Int J Med Sci. 2019;16(1):115-24. DOI: 10.7150/ijms.28735Search in Google Scholar
Habrowska-Górczyńska DE, Kozieł MJ, Kowalska K, Piastowska-Ciesielska AW. FOXO3a and its regulators in prostate cancer. Int J Mol Sci. 2021;22(22). DOI: 10.3390/ijms222212530Search in Google Scholar
Chan J, Zaidi S, Love J, Zhao J, Setty M, Wadosky K, et al. Lineage plasticity in prostate cancer depends on FGFR and JAK/STAT inflammatory signaling. Eur J Cancer. 2022;174(6611):S4-5. DOI: 10.1016/S0959-8049(22)00818-8Search in Google Scholar
Hoshi S, Meguro S, Imai H, Matsuoka Y, Yoshida Y, Onagi A, et al. Upregulation of glucocorticoid receptor-mediated glucose transporter 4 in enzalutamide-resistant prostate cancer. Cancer Sci. 2021;112(5):1899-910. DOI: 10.1111/cas.14865Search in Google Scholar
Bonaterra GA, Schleper A, Skowronek M, Kilian LS, Rink T, Schwarzbach H, et al. Increased Density of Growth Differentiation Factor-15+ Immunoreactive M1/M2 Macrophages in Prostate Cancer of Different Gleason Scores Compared with Benign Prostate Hyperplasia. Cancers (Basel). 2022;14(19). DOI: 10.3390/cancers14194591Search in Google Scholar
Mahon KL, Sutherland SIM, Lin HM, Stockler MR, Gurney H, Mallesara G, et al. Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancer. Prostate. 2024;84(8):747-55. DOI: 10.1002/pros.24691Search in Google Scholar
Meyer-Siegler KL, Iczkowski KA, Leng L, Bucala R, Vera PL. Inhibition of Macrophage Migration Inhibitory Factor or Its Receptor (CD74) Attenuates Growth and Invasion of DU-145 Prostate Cancer Cells. J Immunol. 2006;177(12):8730-9. DOI: 10.4049/jimmunol.177.12.8730Search in Google Scholar
Meyer-Siegler KL, Bellino MA, Tannenbaum M. Macrophage migration inhibitory factor evaluation compared with prostate specific antigen as a biomarker in patients with prostate carcinoma. Cancer. 2002 Mar 11;94(5):1449-56. DOI: 10.1002/cncr.10354Search in Google Scholar
Muramaki M, Miyake H, Yamada Y, Hara I. Clinical utility of serum macrophage migration inhibitory factor in men with prostate cancer as a novel biomarker of detection and disease progression. Oncol Rep. 2006 Jan 1;253-7. DOI: 10.3892/or.15.1.253Search in Google Scholar
Tekin B, Dasari S, Theis JD, Vrana JA, Murray DL, Oglesbee D, et al. Mass spectrometry-based assessment of prostate cancer-associated crystalloids reveals enrichment for growth and differentiation factor 15. Hum Pathol. 2023;135:35-44. DOI: 10.1016/j.humpath.2023.03.001Search in Google Scholar
Meyer-Siegler KL, Iczkowski KA, Vera PL. Further evidence for increased macrophage migration inhibitory fator expression in prostate cancer. BMC Cancer. 2005;5:1-12. Available from: DOI: 10.1186/1471-2407-5-73 DOI: 10.1186/1471-2407-5-73Search in Google Scholar
Zhou B, Ren C, Zu L, Zheng L, Guo L, Gao W. Elevated plasma migration inhibitory factor in hypertension-hyperlipidemia patients correlates with impaired endothelial function. Medicine (Baltimore). 2016 Oct;95(43):e5207. DOI: 10.1097/MD.0000000000005207Search in Google Scholar
Herder C, Kolb H, Koenig W, Haastert B, Müller-Scholze S, Rathmann W, et al. Association of Systemic Concentrations of Macrophage Migration Inhibitory Factor With Impaired Glucose Tolerance and Type 2 Diabetes. Diabetes Care. 2006 Feb 1;29(2):368-71. DOI: 10.2337/diacare.29.02.06.dc05-1474Search in Google Scholar
Sarkar S, Legere S, Haidl I, Marshall J, Macleod JB, Aguiar C, et al. Serum GDF15, a promising biomarker in obese patients undergoing heart surgery. Front Cardiovasc Med. 2020;7(June). DOI: 10.3389/fcvm.2020.00103Search in Google Scholar
Bansal N, Kumar D, Gupta A, Chandra D, Sankhwar SN, Mandhani A. Relevance of MIC-1 in the Era of PSA as a Serum Based Predictor of Prostate Cancer: A Critical Evaluation. Sci Rep. 2017 Dec 4;7(1):16824. DOI: 10.1038/s41598-017-17207-2Search in Google Scholar
Song H, Shen Q, Hu S, Jin J. The role of macrophage migration inhibitory factor in promoting benign prostatic hyperplasia epithelial cell growth by modulating COX-2 and P53 signaling. Biol Open. 2020;9(11):1-7. DOI: 10.1242/bio.053447Search in Google Scholar
Sörensen-Zender I, Beneke J, Schmidt BM, Menne J, Haller H, Schmitt R. Zinc-alpha2-glycoprotein in patients with acute and chronic kidney disease. BMC Nephrol. 2013;14(1):1-6. DOI: 10.1186/1471-2369-14-145Search in Google Scholar
Ji D, Li M, Zhan T, Yao Y, Shen J, Tian H, et al. Prognostic role of serum AZGP1, PEDF and PRDX2 in colorectal cancer patients. Carcinogenesis. 2013;34(6):1265-72. DOI: 10.1093/carcin/bgt056Search in Google Scholar